U.S. The Food and Drug Administration’s advisory committee on Thursday voted in favor of the Pfizer-Bioentech coronavirus vaccine, with FDA leaders clarifying how to authorize the large-scale distribution of the emergency amid a steady rise in the number of Covid-1 cases across the country.
In a joint statement released after the vote, FDA Commissioner Dr. Step. Stephen Hahn and Dr. Peter Mark, director of the FDA’s Center for Biologics Evaluation and Research, said the agency would now work toward finalizing and issuing emergency use authorizations. ”
Quick facts
- The recommendation clears the way for FDA leaders to authorize emergency mass distribution
- Vaccine shipments will begin within hours of the FDA’s decision, which could arrive as early as Friday.
- The Firefire vaccine will be available in limited quantities, with initial doses for frontline health care workers and high-risk patients.
Vaccine shipments will begin within hours of the FDA’s decision, which could arrive as early as Friday, followed immediately by the first vaccination. The Firefly vaccine will be available in limited quantities, with initial doses for frontline health care workers and high-risk patients.
In November, Pfizer announced that its coronavirus vaccine was 95 percent effective and had not exhibited any major side effects.
Follow below for updates about the coronavirus epidemic. Mobile users click here.
